EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to conventional dose radiotherapy for clinically localized prostate cancer



Multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to conventional dose radiotherapy for clinically localized prostate cancer



Journal of Urology 171(4 Supplement): 312, April




(PDF 0-2 workdays service: $29.90)

Accession: 035349722

Download citation: RISBibTeXText



Related references

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 60(1): 15-23, 2004

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 73(2): 327-333, 2008

Preliminary report of a multi center Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen ablation prior to standard dose radiotherapy for clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics 54(2 Supplement): 134, 2002

Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. Journal of Clinical Oncology 25(1): 77-84, 2006

Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?. Strahlentherapie und Onkologie 183 Spec No 2: 26-28, 2008

A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon®) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for biochemical recurrence following radical local therapy. Journal of Urology, 2018

The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy neoadjuvant androgen deprivation. International Journal of Radiation Oncology*biology*physics 58(1): 53-58, 2004

The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation. International Journal of Radiation Oncology, Biology, Physics 58(1): 53-58, 2003

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology 24(13): 1990-1996, 2006

Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: An interim report. Journal of Clinical Oncology 24(18_suppl): 4607-4607, 2016

Sequencing of short course androgen deprivation and high-dose external beam radiotherapy for unfavorable localized prostate cancer Adjuvant or neoadjuvant. International Journal of Radiation Oncology Biology Physics 54(2 Supplement): 256, 2002

Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study. British Journal of Urology 79(3): 432-438, 1997

Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 16(6): 516-522, 1993

The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Medica Okayama 61(6): 335-340, 2008

The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Medica Okayama 61(6): 335-340, 2007